Type 1 and Type 2 Diabetes Nutritional, Metabolic, Endocrine Type 1 and Type 2 Diabetes
Conditions
Interventions
Participants are randomly allocated to one of five groups based on intervention type and dosage level.
Those in the first two groups receive the ‘treatment’ condition: a tailored-for-
they act as the ‘control’ condition. All participants (with the exception of the placebo group) complete the task as frequently as they have been told to do for a period of four weeks. All participant
Sponsors
Liverpool John Moores University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Mentally healthy adults over the age of 18 with a formal diagnosis of type 1 or type 2 diabetes 2. Participants must already be daily self-monitoring their blood sugar levels 3. They must also regularly receive HbA1c levels from their health care professional (e.g. GP or nurse)
Exclusion criteria
Exclusion criteria: 1. Under the age of 18 2. Have a form of diabetes not listed in the inclusion criteria such as gestational diabetes. This is simply because they are less common, preventing an easy split of the data. 3. Anyone with an affective disorder (e.g. anxiety, depression, eating disorders; all of which are common co-morbidities of diabetes) will also be excluded because of the nature of the study (i.e. a trial with a focus on emotions and emotion induction) as they might be at too much undue risk
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Positive psychological changes are measured using the PANAS questionnaire at baseline, immediately after allocation to assess exposure effects, and trial end (end of week 4) 2. Depression and anxiety levels are measured using the HADS questionnaire at baseline and trial end (end of week 4) 3. Self-Management behaviours are measured using the DSMQ questionnaire at baseline and trial end (end of week 4) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Blood sugar control is measured using changes in daily self-reported blood sugar results and changes in HbA1c results (if available) across the duration of the trial. Participants provide their last fasting and pre-prandial blood sugar results at baseline and then self-report subsequent results once a week in response to a reminder email. They provide their previous HbA1c at baseline and report any changes (if there were any during the trial period) at trial end (end of week 4). | — |
Countries
Australia, Canada, England, France, Germany, Italy, Netherlands, New Zealand, Spain, United Kingdom, United States of America
Contacts
Public ContactBenjamin Gibson
Outcome results
None listed